Karel Van Damme
- Work address
-
Technologiepark-Zwijnaarde 75, uitbreiding VIB + r
9052 Zwijnaarde - Karel.VanDamme@UGent.be
- ORCID iD
-
0000-0002-4379-1047
Show
Sort by
-
- Journal Article
- A1
- open access
TIM3+ TRBV11-2 T cells and IFNγ signature in patrolling monocytes and CD16+ NK cells delineate MIS-C
-
Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID) : a factorial, randomised, controlled trial
-
- Journal Article
- A1
- open access
Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19 : a meta-analysis
-
Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC) : a structured summary of a study protocol for a randomised controlled trial (vol 21, 491, 2020)
-
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID) : a structured summary of a study protocol for a randomised controlled trial (vol 21, 468, 2020)
-
- Journal Article
- A1
- open access
Zilucoplan in patients with acute hypoxic respiratory failure due to COVID-19 (ZILU-COV) : a structured summary of a study protocol for a randomised controlled trial
-
- Journal Article
- A1
- open access
Case report : convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19
-
- Journal Article
- A1
- open access
Treatment of severely ill COVID-19 patients with anti-interleukin drugs (COV-AID) : a structured summary of a study protocol for a randomised controlled trial
-
- Journal Article
- A1
- open access
Sargramostim to treat patients with acute hypoxic respiratory failure due to COVID-19 (SARPAC) : a structured summary of a study protocol for a randomised controlled trial